About Pervasis Therapeutics
Pervasis Therapeutics is developing biologically active therapeutics to regulate vascular repair and restore blood flow to critical organs and vasculature. The company's flagship product, Vascugel, is a cell-based therapeutic matrix developed to reestablish healthy vasculature after vascular injury. Per the company, Vascugel has the capability to be delivered in both open surgical and minimally invasive procedures. Pervasis is also exploring broader indications in non-vascular applications.
Missing: Pervasis Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Pervasis Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Pervasis Therapeutics News
Apr 20, 2012
XconomyBoston — Last week brought good news for two Cambridge, MA companies pursuing different methods for repairing damaged body parts. Pervasis Therapeutics, which developed a cell-based method for fixing blood vessels, was acquired by Irish drug giant Shire (NASDAQ: SHPGY ) on April 12. The next day, Cambridge-based InVivo Therapeutics (OTCBB: NVIV ) said it expected it would soon win clearance from the FDA to begin human trials of the spinal cord injury treatment it has been working on for years. Both companies emanated from the lab of Robert Langer, MIT professor and prolific entrepreneur (as well as one of our Xconomists ), and both have experienced the ups and downs typical in the regenerative-medicine world. InVivo hoped to begin human testing of its implant for spinal cord injury patients in 2009, but was delayed by a lack of funding, as well as lengthy discussions with the FDA about the trial protocol. Pervasis raised $46 million in venture capital from the likes of Polaris Venture Partners. In 2010, the company received permission from the FDA to begin pivotal trials of its lead product, Vascugel, but it struggled to find a partner to finance the project. For Shire, acquiring Pervasis helps to boost the drug company’s growing capabilities in cell-based therapeutics, says Kevin Rakin, president of Shire’s regenerative medicine unit. Pervasis’ technology employs endothelial cells from the lining of blood vessels to promote healing of injuries caused by inflammation, scaring, or vascular disease. The lead indication is for patients with kidney disease who are undergoing hemodialysis. Vascugel is designed to improve the function of so-called AV grafts—dialysis access points that are created by connecting veins and arteries with plastic tubes. “About 50 percent of those grafts don’t last the first year,” Rakin says. “But when Pervasis’ cells are wrapped around those access points, it improves healing. As more patients are going into dialysis, it will become more important to prevent grafts from collapsing and to extend their life.” Rakin says Shire bought Pervasis for a modest up-front payment, plus milestone payments that could be worth up to $200 million, pending certain developmental, regulatory, and sales achievements. Rakin adds that Pervasis is a good fit for an earlier Shire acquisition in the regenerative-medicine realm, Advanced BioHealing, which the company bought for $750 million last year. That deal brought Shire the product Dermagraft, which treats … Next Page »
Pervasis Therapeutics Frequently Asked Questions (FAQ)
When was Pervasis Therapeutics founded?
Pervasis Therapeutics was founded in 2003.
Where is Pervasis Therapeutics's headquarters?
Pervasis Therapeutics's headquarters is located at One Kendall Square, Cambridge.
What is Pervasis Therapeutics's latest funding round?
Pervasis Therapeutics's latest funding round is Acquired.
How much did Pervasis Therapeutics raise?
Pervasis Therapeutics raised a total of $39.65M.
Who are the investors of Pervasis Therapeutics?
Investors of Pervasis Therapeutics include Shire, Flagship Pioneering, Polaris Partners, Highland Capital Partners, Richter Family Fund and 4 more.
Who are Pervasis Therapeutics's competitors?
Competitors of Pervasis Therapeutics include OcuNexus Therapeutics, Acorda Therapeutics, Gamida Cell, NellOne Therapeutics, Synapsin Pharmaceuticals and 12 more.
Compare Pervasis Therapeutics to Competitors
SYNAPSIN is developing therapeutic strategies for the treatmentand prevention ofneurodegenerative disorders such as Alzheimer's disease (AD),Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and spinal cord injury.
Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.
Richwood develops drugs for disorders of the central nervous system, particularly hyperactivity in children.
Rimon Therapeutics, through the application of its polymer chemistry platform, is developing therapeutics to address unmet needs in important disease indicators with large markets. Rimon's therapeutic polymers - trademarked Theramers - are in that they deliver therapeutic effect without incorporating or releasing drugs. Theramers are intended to be used as solids-scaffolds, microbeeds and coatings - acting locally, without systemic consequences.
CoPlex Therapeutics is focused on R&D to provide neuroprotection from dementia caused by a protein complex that accumulates in the central nervous system and begins the cascade effect that leads to dementia including Alzheimer's.
Which is using a platform-technology approach to develop antibody and peptide-based therapeutics against select targets.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.